Seattle Police, 1918-19 |
GUEST BLOG / By Mark
Terry, writer with Biospace.com--The world is currently battling a global
pandemic of SARS-CoV-2, the novel coronavirus that causes COVID-19. As of April
1, 2020, there are 921,924 confirmed cases of COVID-19 worldwide with 46,252
total deaths. In the United States, there are 186,101 cases with a total of
3,603 deaths.
At
this time, vast swaths of the U.S. population are under a semi-quarantine
dubbed “social distancing,” with most businesses closed except for essential
businesses, such as hospitals and doctors’ offices, grocery stores, banks and
utilities. Many people are working from home, if able. The goal is to “flatten
the curve,” which refers to various graphs of the outbreak which show a very
steep curve that would concentrate the number of cases diagnosed and treated in
a very short period of time, which would overwhelm hospitals. By flattening the
curve, the outbreak’s spread would be slowed, and cases would be spread out over
a longer period of time in hopes of giving healthcare institutions the ability
to better manage the cases.
Computer
models projecting the COVID-19 range dramatically, with one out of Imperial
College of London predicting about 2.2 million deaths in the U.S. if no action
was taken to slow the spread of the disease. A more hopeful but still
catastrophic model projects somewhere between 100,000 to 240,000 deaths, some
of which come out of the Trump administration and some which came from the
University of Washington’s Institute for Health Metrics and Evaluation (IHME)
and other sources.
The
IHME model, for example, doesn’t take into consideration federal
social-distancing recommendations, but instead looks at a state-by-state basis,
because some states have taken very aggressive and early actions, such as Ohio,
Michigan, Illinois and California, while others, such as Florida, have been
very late to do anything. The IHME model, however, assumes that by April 7 all
states will have imposed a full variety of social-distancing rules.
Although
the IHME projection suggests that in many states the pandemic will have peaked
in mid to late-April, Chris Murray, IHME’s director, told NPR, “Our rough guess
is that come June, at least 95% of the U.S. will still be susceptible. That
means, of course, it can come right back. And so, then we really need to have a
robust strategy in place to not have a second wave.”
Spanish Flu of 1918
Compared to COVID-19
Although
the world has faced several major pandemics over the last 100 years, one of the
worst was the 1918 influenza pandemic, the so-called Spanish flu. It was caused
by an H1N1 virus that originated in birds. It was first identified in the U.S.
in military personnel in the spring of 1918. It was dubbed the Spanish flu because
it was thought at the time to have originated in Spain. Research published in
2005 suggest it actually originated in New York. It was named Spanish flu
because Spain was neutral in World War I (1914-1918), meaning it could report
on the severity of the pandemic, but countries fighting the war were
suppressing reports on how the disease affected their populations.
At
its worse, the Spanish flu infected 500 million people worldwide, which at the
time was about a third of the Earth’s population. More than 50 million people
died of the disease, with 675,000 in the U.S. There is some disagreement on
that figure, with recent researchers suggesting it was about 17.4 million
deaths, while others go as high as 100 million. Generally speaking, the
fatality rate for the Spanish flu is calculated at about 2%.
Although
it is something of a moving target as more deaths occur and broader diagnostic
testing is performed, finding higher levels of infection, sometimes with no
symptoms, the global fatality rate for COVID-19 as of April 1 is about 5%,
although in the U.S. it is about 2.16%. Some experts believe the 5% figure is
significantly lower because of doubts about the accuracy of China’s reporting
of the cases, where COVID-19 originated.
Some
experts, such as Anthony Fauci, director of the U.S. National Institute of
Allergy and Infectious Diseases, who is something of the public point-man for
the U.S. response to COVID-19, project the fatality rate will be about 1%,
which is still about 10 times the fatality rate of a typical seasonal influenza
of 0.1%.
Another
commonality between the Spanish flu’s H1N1 and the COVID-19 coronavirus is that
both are considered “novel,” which is to say, they are so new nobody in either
era had any immunity to them. One marked difference between the two is the most
affected groups in the 1918 pandemic were otherwise healthy adults between the
ages of 20 to 40. Mortality was also higher in people younger than five years
of age and 65 and older.
“The
1918 pandemic strain influenza was new and novel for most people under the age
of 40 or 50, but that’s where the death rate really was high—that’s different
than the usual flu,” Mark Schleiss, a pediatric infectious disease specialist
at the University of Minnesota told Healthline.
Demographics of the
Pandemics
The
most affected groups for COVID-19 are adults over the age of 65 with underlying
health conditions. For the most part, children seem to have much milder
symptoms.
There
were no vaccines for the Spanish flu and there are currently no vaccines for
COVID-19. One reason the Spanish flu was so lethal was there were no
antibiotics to treat secondary bacterial infections, so control efforts around
the globe were limited to non-pharmaceutical responses like isolation,
quarantine, disinfectants and limiting public gatherings, although then as now,
they were applied erratically. The first flu vaccine to be licensed in the U.S.
came about in the 1940s.
The
1918 pandemic ended in the summer of 1919, mostly, Healthline reports, due to
deaths and higher immunity levels. Christine Kreuder Johnson, a University of
California - Davis professor of epidemiology and ecosystem health and a
researcher on USAID’s Emerging Pandemic Threats PREDICT project, said that
another thing to take into consideration for the 1918 pandemic was the world
was in the middle of a war and soldiers were spreading the virus globally.
People also lived in crowded conditions and had extremely poor hygiene.
To
date, about 1.25 million people have been confirmed to have COVID-19 worldwide,
with about more than 66,000 deaths. Of course, the world population in 1918 was
about 1.8 billion. The higher estimate of 50 million deaths would suggest the
Spanish flu killed 2.7% of the world population, while the 17.4 million figure
suggest about 1%.
The
current world’s population is about 8 billion people with significantly lower
death rates from COVID-19 overall. Although the pandemic is far from over, the
lower figure is likely related to greater awareness of how viruses and
pandemics work, better healthcare, both in terms of access to hospitals, but
antibiotics, antiviral drugs and other approaches to treating diseases. In
fact, although healthcare facilities are being stretched thin by COVID-19 in
many countries, it was quite a bit worse in 1918, as hospitals were dealing
with mass casualties and injuries from the war, and many physicians were with
the troops, leaving medical students to take care of the influenza patients.
On
the other hand, we have a far more connected world with air travel and denser
populations, which make the spread of COVID-19 easier and faster.
Cautions on Comparison
With
all the similarities, it should be emphasized that there are several
significant differences between the two pandemics. First off, simply, is that
COVID-19 is not influenza, it is more like a chronic acute pneumonia. They are
both caused by novel viruses, but different types of viruses with different
methods of action and infectiousness.
Secondly,
and perhaps most importantly, the ability of researchers to marshal technology
and science to quickly develop and/or test drugs for the disease, has never
been as strong as it is now. There are more than 100 ongoing clinical trials
worldwide of experimental and already approved drugs that might be repurposed
to fight COVID-19, with literally dozens of companies globally working on
developing vaccines against the SARS-CoV-2 virus that are already in clinical
trials might be available to battle a second wave of the disease, although that
will depend on when or if there is a second wave and when or if a vaccine is
developed. Many experts believe a second wave is possible in the fall of 2020,
and most optimistic projections don't have a vaccine available until early
2021, although that will depend a great deal on the types of technologies
available, clinical trial results, and the world's willingness to rush
regulations in the face of an emergency.
In
fact, one of the primary pharmaceutical treatments for the Spanish flu was
aspirin, which had been trademarked by Bayer in 1899, but whose patent expired
in 1917, allowing companies to manufacturing it during the pandemic. At the
time, medical professionals were recommending up to 30 grams of aspirin daily,
which we now know is toxic—doses above four grams are unsafe. Aspirin poisoning
symptoms include hyperventilation and pulmonary edema (fluid in the lungs), so
many medical historians believe many of the deaths from the Spanish flu were
either caused or accelerated by aspirin poisoning.
Global
communication and sharing of information are also significantly better than in
1918, which has seen researchers sharing data on the pandemic, the virus and
numerous drugs, and governments doing the same.
The
COVID-19 epidemic is without a doubt an enormous and unique challenge
worldwide, and the battle is nowhere near being over. But there are signs that
government policies in several countries, including Germany and South Korea,
have been able to contain the virus, and news about several antiviral drug
trials, such as Gilead Sciences’ remdesivir, are expected in the next few
weeks, should give people hope. Even in China, where the pandemic appears to
have originated, seems three months later, to have things largely under
control.
As
Ross Douthat wrote in The New York Times on March 28, there are signs of what
he calls “rational hope,” which “is not the same as reckless optimism. It
doesn’t require, for instance, quickly lifting quarantines based on outlying
projections of low fatality rates, as some return-to-normalcy conservatives
have been doing in the last week. Rational hope accepts that the situation is
genuinely dark, but then it still looks around for signposts leading up and
out. It recognizes that things are likely to get worse but keeps itself alert
to the contexts in which they seem to be getting better—or at the very least,
getting worse more slowly.”
And
as has been pointed out, pandemics, from the 1918 Spanish flu to the H1N1
pandemic of 2009, do end. Sometimes with seemingly unbearable numbers of
deaths, but eventually they do end.
No comments:
Post a Comment